Yuichi Ishikawa

Yuichi Ishikawa

Auto-generated profile, based on publicly available information

Yuichi Ishikawa

Nagoya University Graduate School of Medicine

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
YIYuichi Ishikawa
Yuichi Ishikawa
NKNaomi Kawashima
Naomi Kawashima
YAYoshiko Atsuta
Yoshiko Atsuta
ISIsamu Sugiura
Isamu Sugiura
MSMasashi Sawa
Masashi Sawa
HKHitoshi Kiyoi
Hitoshi Kiyoi
Key Points: KIT exon 17 mutation is a poor prognostic factor in AML patients with RUNX1-RUNX1T1, but not in those with CBFB-MYH11. NRAS mutation is a poor prognostic factor in AML patients with CBFB-MYH11.

9 January 2025 in JCI Insight
Verified
Journal Article
Open access
TSTakahiko Sato
Takahiko Sato
DSDaisuke Sugiyama
Daisuke Sugiyama
JKJun Koseki
Jun Koseki
YKYasuhiro Kojima
Yasuhiro Kojima
SHSatomi Hattori
Satomi Hattori
HNHiroyoshi Nishikawa
Hiroyoshi Nishikawa
Tumor-associated macrophages (TAMs) are one of the key immunosuppressive components in the tumor microenvironment (TME) and contribute to tumor development, progression, and resistance to cancer immunotherapy. Several reagents targeting TAMs have been tested in preclinical and clinical studies, but they have had limited success. Here, we show that a unique reagent, FF-10101, exhibited a sustained inhibitory effect against colony-stimulating factor 1 receptor by forming a covalent bond and reduced immunosuppressive TAMs in the TME, which led to strong antitumor immunity. In preclinical animal models, FF-10101 treatment significantly reduced immunosuppressive TAMs and increased antitumor TAMs in the TME. In addition, tumor antigen-specific CD8 + T cells were increased; consequently, tumor growth was significantly inhibited. Moreover, combination treatment with an anti–programmed cell death 1 (anti–PD-1) antibody and FF-10101 exhibited a far stronger antitumor effect than either treatment alone. In human cancer specimens, FF-10101 treatment reduced programmed cell death 1 ligand 1 (PD-L1) expression on TAMs, as observed in animal models. Thus, FF-10101 acts as an immunomodulatory agent that can reduce immunosuppressive TAMs and augment tumor antigen-specific T cell responses, thereby generating an immunostimulatory TME. We propose that FF-10101 is a potential candidate for successful combination cancer immunotherapy with immune checkpoint inhibitors, such as PD-1/PD-L1 blockade.

21 January 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
ISIsamu Sugiura
Isamu Sugiura
NDNoriko Doki
Noriko Doki
THTomoko Hata
Tomoko Hata
RCRyuko Cho
Ryuko Cho
TIToshiro Ito
Toshiro Ito
YMYasushi Miyazaki
Yasushi Miyazaki
The standard treatment for adults with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) in Japan is imatinib-based chemotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT). However, ∼40% of patients cannot undergo HSCT in their first complete remission (CR1) because of chemotherapy-related toxicities or relapse before HSCT or older age. In this study, we evaluated dasatinib-based 2-step induction with the primary end point of 3-year event-free survival (EFS). The first induction (IND1) was dasatinib plus prednisolone to achieve CR, and IND2 was dasatinib plus intensive chemotherapy to achieve minimal residual disease (MRD) negativity. For patients who achieved CR and had an appropriate donor, HSCT during a consolidation phase later than the first consolidation, which included high-dose methotrexate, was recommended. Patients with pretransplantation MRD positivity were assigned to receive prophylactic dasatinib after HSCT. All 78 eligible patients achieved CR or incomplete CR after IND1, and 52.6% achieved MRD negativity after IND2. Nonrelapse mortality (NRM) was not reported. T315I mutation was detected in all 4 hematological relapses before HSCT. Fifty-eight patients (74.4%) underwent HSCT in CR1, and 44 (75.9%) had negative pretransplantation MRD. At a median follow-up of 4.0 years, 3-year EFS and overall survival were 66.2% (95% confidence interval [CI], 54.4-75.5) and 80.5% (95% CI, 69.7-87.7), respectively. The cumulative incidence of relapse and NRM at 3 years from enrollment were 26.1% and 7.8%, respectively. Dasatinib-based 2-step induction was demonstrated to improve 3-year EFS in Ph+ ALL. This study was registered in the UMIN Clinical Trial Registry as #UMIN000012173.

17 June 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
FCFangli Chen
Fangli Chen
YIYuichi Ishikawa
Yuichi Ishikawa
AAAkimi Akashi
Akimi Akashi
TNTomoki Naoe
Tomoki Naoe
HKHitoshi Kiyoi
Hitoshi Kiyoi
FLT3 mutation is found in about 30% of acute myeloid leukemia (AML) patients and is associated with a poor prognosis. Several FLT3 inhibitors are undergoing investigation, while their clinical efficacies were lower than expected and several resistant mechanisms to FLT3 inhibitors have been demonstrated. Although most AML cells harboring FLT3 mutation co-express wild-type (Wt)-FLT3, it is not fully understood how Wt-FLT3 expression is associated with the resistance to FLT3 inhibitors. In this study, we elucidated a resistant mechanism by which FL-dependent Wt-FLT3 activation reduced inhibitory effects of FLT3 inhibitors. We demonstrated that FL-stimulation much more strongly reduced growth inhibitory effects of FLT3 inhibitors on Wt- and mutant-FLT3 co-expressing cells than sole mutant-FLT3 expressing cells both in vitro and in vivo. It was also confirmed that FL impaired the anti-leukemia effects of FLT3 inhibitors on primary AML cells. We elucidated that FL impeded the inhibitory effects of FLT3 inhibitors mainly through the activation of Wt-FLT3, but not mutated FLT3, in the Wt- and ITD-FLT3 co-expressing cells. Furthermore, FL-induced activation of Wt-FLT3-MAPK axis was the dominant pathway for the resistance, and the glycosylation of Wt-FLT3 was also vital for FL-dependent kinase activation and following resistance to FLT3 inhibitors. Thus, we clarified the importance of co-expressing Wt-FLT3 in resistance to FLT3 inhibitors. These findings provide us with important implications for clinical application and new strategies to improve clinical outcomes of FLT3 inhibitors.

25 March 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
NKNaomi Kawashima
Naomi Kawashima
YIYuichi Ishikawa
Yuichi Ishikawa
JKJeong Hui Kim
Jeong Hui Kim
YUYoko Ushijima
Yoko Ushijima
AAAkimi Akashi
Akimi Akashi
HKHitoshi Kiyoi
Hitoshi Kiyoi
Patient-derived xenografts (PDX) are widely used as human cancer models. Previous studies demonstrated clonal discordance between PDX and primary cells. However, in acute myeloid leukemia (AML)-PDX models, the significance of the clonal dynamics occurring in PDX remains unclear. By evaluating changes in the variant allele frequencies (VAF) of somatic mutations in serial samples of paired primary AML and their PDX bone marrow cells, we identify the skewing engraftment of relapsed or refractory (R/R) AML clones in 57% of PDX models generated from multiclonal AML cells at diagnosis, even if R/R clones are minor at <5% of VAF in patients. The event-free survival rate of patients whose AML cells successfully engraft in PDX models is consistently lower than that of patients with engraftment failure. We herein demonstrate that primary AML cells including potentially chemotherapy-resistant clones dominantly engraft in AML-PDX models and they enrich pre-existing treatment-resistant subclones.

26 July 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
YAYoshiya Adachi
Yoshiya Adachi
YIYuichi Ishikawa
Yuichi Ishikawa
HKHitoshi Kiyoi
Hitoshi Kiyoi
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Yoshiya Adachi1, Yuichi Ishikawa1 and Hitoshi Kiyoi1 1Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan Correspondence to: Yuichi Ishikawa, email: yishikaw@med.nagoya-u.ac.jp Keywords: AML, PLK1 inhibitor, volasertib, resistance, MDR1 Received: March 06, 2017 Accepted: July 03, 2017 Published: July 26, 2017 ABSTRACT Volasertib, a selective PLK1 inhibitor, was effective for acute myeloid leukemia (AML) patients in clinical trials. However, its efficacy was limited in mono-therapy, and a higher incidence of fatal events was revealed in the combination with low-dose cytarabine. Thus, optimization of combination therapy with volasertib and other agents is necessary for its clinical development, and the predictive factors for response or resistance to volasertib remain largely unknown. In this study, we investigated the resistance mechanism in volasertib-resistant cell lines and the combination effects with other agents, such as azacitidine (AZA), on AML cells. We identified that mutations in the ATP-binding domain of PLK1 and expression of MDR1 conferred resistance to volasertib. In the combination therapy, the effects of AZA differed among cells, but were prominent in the cells with higher GI50 values of volasertib in mono-therapy. Furthermore, we identified that the cells in G2/M phase were more sensitive to volasertib, and the PI3K/AKT pathway was up-regulated upon administration of volasertib. Combination therapies with the agents that caused cell cycle accumulation in G2/M phase or with PI3K inhibitor were highly potent against AML cells. Our findings provide strategies for further clinical development of volasertib and PLK inhibitors for AML.